Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation
Drug Encapsulation System
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Dolomite Microfluidics is simplifying research into drug encapsulation by offering a complete automated system for polymer micro- and nanoparticle generation. The company’s Drug Encapsulation System provides scientists with a quick, simple and scalable way of encapsulating drug samples, without the need for extensive microfluidics knowhow.
The Drug Encapsulation System has been developed specifically to meet the demands of the drug development sector. It draws on Dolomite’s extensive microfluidics expertise to create a straightforward and flexible solution that offers ‘plug and play’ encapsulation of drugs into biodegradable polymeric particles (e.g. PLGA). The exceptional process control offered by this system allows reliable and reproducible generation of polymer particles with a narrow size distribution, and enables the user to ‘tune’ particle size from 50 nm to 100 μm to suit their application. This approach ensures high product purity and uniform API distribution, with almost 100 % encapsulation efficiency, simplifying optimization and validation studies. Once these studies are complete, the process can be readily scaled up using Dolomite’s Telos® High Throughput Droplet System. Backed by the company’s in-depth knowledge of the drug development market, these technologies put microfluidics-based drug encapsulation within reach for virtually any laboratory.
Mark Gilligan, CEO of Dolomite, commented: “For over 15 years, we have been developing microfluidic technologies to provide reproducible particle synthesis, efficient API distribution and easy scale-up – all critical considerations for drug delivery applications. With Dolomite technology, microencapsulation has never been easier.”
The Drug Encapsulation System has been developed specifically to meet the demands of the drug development sector. It draws on Dolomite’s extensive microfluidics expertise to create a straightforward and flexible solution that offers ‘plug and play’ encapsulation of drugs into biodegradable polymeric particles (e.g. PLGA). The exceptional process control offered by this system allows reliable and reproducible generation of polymer particles with a narrow size distribution, and enables the user to ‘tune’ particle size from 50 nm to 100 μm to suit their application. This approach ensures high product purity and uniform API distribution, with almost 100 % encapsulation efficiency, simplifying optimization and validation studies. Once these studies are complete, the process can be readily scaled up using Dolomite’s Telos® High Throughput Droplet System. Backed by the company’s in-depth knowledge of the drug development market, these technologies put microfluidics-based drug encapsulation within reach for virtually any laboratory.
Mark Gilligan, CEO of Dolomite, commented: “For over 15 years, we have been developing microfluidic technologies to provide reproducible particle synthesis, efficient API distribution and easy scale-up – all critical considerations for drug delivery applications. With Dolomite technology, microencapsulation has never been easier.”
